The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach

[1]  Dan J Stein,et al.  Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review , 2021, Journal of Affective Disorders.

[2]  R. McIntyre,et al.  Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death: A Systematic Review and Meta-analysis. , 2021, JAMA psychiatry.

[3]  D. Goff,et al.  Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis. , 2021, JAMA psychiatry.

[4]  Peter B. Jones,et al.  Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies , 2021, Molecular Psychiatry.

[5]  T. Kishimoto,et al.  Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. , 2021, The lancet. Psychiatry.

[6]  M. Karanikola,et al.  Long acting injectable antipsychotics: Uninterrupted use during the COVID‐19 pandemic , 2021, Journal of psychiatric and mental health nursing.

[7]  L. Smeeth,et al.  Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study , 2021, The Lancet Digital Health.

[8]  O. Freudenreich,et al.  Long-acting injectable antipsychotics during COVID-19 , 2021 .

[9]  D. Goff,et al.  Association of Psychiatric Disorders With Mortality Among Patients With COVID-19. , 2021, JAMA psychiatry.

[10]  E. Vieta,et al.  Changing trends in psychiatric emergency service admissions during the COVID-19 outbreak: Report from a worldwide epicentre , 2020, Journal of Affective Disorders.

[11]  D. Siskind,et al.  Maximizing the Uptake of a COVID-19 Vaccine in People With Severe Mental Illness: A Public Health Priority. , 2020, JAMA psychiatry.

[12]  Paul J. Harrison,et al.  Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA , 2020, The Lancet Psychiatry.

[13]  A. Harris,et al.  Trends in the Use of Telehealth During the Emergence of the COVID-19 Pandemic — United States, January–March 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[14]  K. Gill,et al.  Challenges Experienced by Behavioral Health Organizations in New York Resulting from COVID-19: A Qualitative Analysis , 2020, Community Mental Health Journal.

[15]  K. Baumstarck,et al.  Disparities in Intensive Care Unit Admission and Mortality Among Patients With Schizophrenia and COVID-19: A National Cohort Study , 2020, Schizophrenia bulletin.

[16]  N. Volkow,et al.  Increased risk of COVID‐19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States , 2020, World psychiatry : official journal of the World Psychiatric Association.

[17]  A. Young,et al.  The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. , 2020, The American journal of psychiatry.

[18]  C. Correll,et al.  Management of Patients With Severe Mental Illness During the Coronavirus Disease 2019 Pandemic. , 2020, JAMA psychiatry.

[19]  D. Sarpal,et al.  Ensuring care for clozapine-treated schizophrenia patients during the COVID-19 pandemic , 2020, Schizophrenia Research.

[20]  Jessica M. Gannon,et al.  Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions , 2020, Schizophrenia Research.

[21]  B. Mulsant,et al.  The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders , 2020, Schizophrenia bulletin.

[22]  L. Dima,et al.  Long-acting injectable antipsychotics treatment during COVID-19 pandemic – A new challenge , 2020, Schizophrenia Research.

[23]  Olivia J. Kirtley,et al.  Suicide risk and prevention during the COVID-19 pandemic , 2020, The Lancet Psychiatry.

[24]  A. Carvalho,et al.  The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. , 2019, The lancet. Psychiatry.

[25]  Z. Rihmer,et al.  Suicide Risk in Bipolar Disorder: A Brief Review , 2019, Medicina.

[26]  M. Byerly,et al.  Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2 , 2018, Neuropsychiatric disease and treatment.

[27]  B. Druss,et al.  Psychiatry's Role in Improving the Physical Health of Patients With Serious Mental Illness: A Report From the American Psychiatric Association. , 2018, Psychiatric services.

[28]  Publisher's Note , 2018, Anaesthesia.

[29]  A. Tanskanen,et al.  Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia , 2017, Schizophrenia Research.

[30]  Paolo Santonastaso,et al.  Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls , 2017, World psychiatry : official journal of the World Psychiatric Association.

[31]  J. McGrath,et al.  Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. , 2017, The lancet. Psychiatry.

[32]  Christopher E. Smith.  United States , 1985, The Lancet.

[33]  C. Chepke.  Drive-up pharmacotherapy during the COVID-19 pandemic , 2020 .